Whether CRISPR Therapeutics or related gene-editing equities represent a good purchase depends on an investor's tolerance for high-growth biotech volatility. Bullish analysts point to commercial sales momentum and ground-breaking clinical milestones as strong catalysts, while conservative investors caution that ongoing operating losses and heavy research expenditures require a long-term investment horizon.